NASDAQ OMX

Acapture, Sift Science to Bring Merchants World-Class Fraud Products

Dela

Enabling merchants to achieve higher conversion and authorization rates in real-time by reducing fraud, false positives and operational costs.

Amsterdam, The Netherlands - April 4, 2018 - Acapture, a global, omnichannel payment processor has partnered with Sift Science, a machine learning company that protects businesses from fraud and abuse. Using the smartest technology for fraud management in their joint effort to make online experiences smoother and safer, the two companies form a powerhouse for fighting ecommerce fraud and helping merchants maximize their revenue.

The partnership creates a single platform capable of managing every type of ecommerce fraud facilitated by Sift Science. Acapture's in-house global acquiring solutions offer access to payment data and insights into the payments journey of the end consumer. This data paired up with Sift Science's cutting-edge machine learning models make the ultimate fraud management solution to protect merchants in the fast-paced fraud landscape.

"We're delighted to have Sift Science as our trusted partner for our long-term mission to help merchants to fight fraud and deliver a better consumer experience" said Rudolf Booker, Acapture CEO. "It's a top challenge for them so it's a top priority for us! By working together, we are confident that the practical expertise in fraud management and machine learning of Sift Science combined with the complete insight into the entire transaction flow enabled by Acapture positions us as merchants' first choice for fraud management".

"Acapture's data and our machine learning models will drive business growth by reducing fraud, false positives, and operational costs," said Jason Tan, Sift Science CEO. "Combining our proven technology platforms, merchants automatically know who's trustworthy and risky. They no longer need to make a tradeoff between protecting and growing their business."

Ecommerce fraud has always been merchants' top of mind challenge that keeps on disrupting them from their core business, preventing them from making the most out of their incoming traffic. Due to the limitations on rule-based applications, many genuine transactions are rejected, resulting in legitimate customers being disappointed by their shopping experience. This rigid fraud prevention approach not only has a negative impact on conversion rates, but also on the brand's reputation especially nowadays, with social media platforms giving consumers a powerful voice.  Acapture's partnership with Sift Science aims to reduce the number of genuine customers being blocked and optimize conversions using customized, data enriched machine learning models. Merchants can ultimately focus on scaling-up their business and not be distracted by fraud.

###

About Acapture

Launched in 2015, Acapture is a new, modern, international payment service provider focused on maximizing the revenues of merchants around the globe. Acapture is affiliated to Payvision, one of the world's fastest-growing global card acquiring networks. Licensed as a payment institution by the Dutch Central Bank, Acapture combines with Payvision to help merchants grow their business globally. This is done through a complete data-driven omnichannel payment solution, capable of managing a payment at every stage, from checkout to fund collection to settlement.
Acapture's system features SlicePay for simplified allocation of funds to multiple parties from a single transaction, data science management for improved authorization rates, the best of human and machine intelligence platform for fraud detection and conversion optimization a one-day integration using one RESTful API, flexible, consolidated reporting, a streamlined reconciliation process, global card acquiring and the ability to handle 80+ of the most popular alternative payment methods and 150+ transaction currencies.
Together with Payvision, Acapture, was awarded Best PSP at the 2017 MPE Awards in Berlin. Find out more on www.acapture.com and follow Acapture on LinkedInTwitterFacebookYouTube and Corporate blog
For further information, please contact: Alina Geosanu | Corporate Communications Coordinator;
e-mail: alina@payvision.com

About Sift Science

Sift Science is a machine learning company that fuels business growth by protecting businesses and their customers from all vectors of fraud and abuse. Global brands such as Twitter, Airbnb, Yelp!, Shutterstock, Jet.com, Indeed and Wayfair rely on the Sift Science Digital Trust Platform for access to a global network of fraud data, 16,000+ fraud signals, and our unique ability to detect and prevent fraud in real time. Our platform was designed in accordance with industry best security practices, including SOC 2. To learn more, visit siftscience.com.

Find out more on https://siftscience.com/. For further information, please contact: Kristina Richmann, Pan Communications (for Sift Science): Kristina Richmann <krichmann@pancomm.com>




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acapture BV via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Hoylu AB: HOYLU HIRES NEW CTO, SATOSHI NAKAJIMA AND ANNOUNCES EXPANSION INTO JAPAN14.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 14, 2018 - Hoylu, a leading enterprise collaboration company, announced today Satoshi Nakajima will join Hoylu in the newly created position, as Chief Technology Officer and President of Hoylu Japan. Nakajima will guide the strategic technology direction and innovation of Hoylu while also leading the new Hoylu office in Tokyo, Japan. "Satoshi is a visionary and world-class technologist who has substantial experience in delivering world class innovations. He is joining the Company as we are extending our reach and expanding into Japan," said Stein Revelsby, CEO. "Satoshi's extensive experience in strategy and delivering technology that support a great user experience will make an immediate impact on the company." Nakajima will serve as President of Hoylu Japan and will report to Stein Revelsby. His leadership will strengthen customer relations and help develop new business among emerging and established Japanese companies while strengthening the global position

Hoylu AB: HOYLU ANSTÄLLER SATOSHI NAKAJIMA SOM NY CTO OCH EXPANDERAR TILL JAPAN14.9.2018 08:30Pressmeddelande

Malmö, Sverige, 14 september 2018 - Hoylu, ett ledande företag inom samarbetsmjukvara för företagsmarknaden annonserar idag att Satoshi Nakajima tar anställning som CTO (Chief Technology Officer) och President för Hoylu Japan. Nakajima kommer styra den strategiska inriktningen för företagets produkter och leda innovationsarbetet. Han kommer också leda Hoylus nyöppnade kontor i Tokyo, Japan. Satoshi är en visionär teknologiexpert som har stor erfarenhet av att skapa innovativa lösningar. Han kommer till Hoylu samtidigt som vi utökar marknaden till att även täcka in Japan säger Stein Revelsby, VD. "Satoshis långa och gedigna erfarenhet i strategiska frågor och tekniska lösningar med fokus på användarupplevelse kommer få stor betydelse för oss." Nakajima kommer även att bli President för Hoylu Japan och kommer rapportera till Stein Revelsby. Hans ledarskap kommer stärka existerande kundrelationer och utveckla nya affärer på den japanska marknaden och samtidigt bidra till att flytta fram p

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum